Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
Not Applicable
Terminated
- Conditions
- Polycystic Kidney
- Interventions
- Registration Number
- NCT00801268
- Lead Sponsor
- Zhi-Hong Liu, M.D.
- Brief Summary
Triptolide has been approve effective in animal model.
- Detailed Description
Randomized
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Clinically established ADPKD
- eGFR>30ml/min.
- Chinese nationality
Exclusion Criteria
- Uncontrolled infections
- Non-ADPKD complications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description emodin Emodin - Triptolide Woldifii tripterygium wilfordii TW60mg/d
- Primary Outcome Measures
Name Time Method MRI calculated kidney volume, eGFR Every 3-6months
- Secondary Outcome Measures
Name Time Method End-stage kidney disease (ESRD) every 2months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of triptolide demonstrate efficacy in ADPKD animal models?
How does tripterygium wilfordii compare to standard-of-care treatments for autosomal dominant polycystic kidney disease?
Which biomarkers correlate with response to triptolide in polycystic kidney disease research?
What adverse events are associated with triptolide treatment in chronic kidney disease trials?
Are there combination therapies involving emodin and other PKD-targeting compounds in clinical development?
Trial Locations
- Locations (2)
Liu ZH, Yao XD,Chen X,Hu YL
🇨🇳Nanjing, Jiangsu, China
Yao Xiaodan
🇨🇳Nanjing, Jiangsu, China
Liu ZH, Yao XD,Chen X,Hu YL🇨🇳Nanjing, Jiangsu, China